Despite advances in antiretroviral therapy that have revolutionized HIV disease
management, effective control of the HIV infection pandemic remains elusive. Beyond the …

Resistance to antiretroviral drugs is an increasingly prevalent challenge affecting both the
adult and pediatric HIV-infected populations. Though data on the safety, pharmacokinetics …

Background Transition to dolutegravir-based regimens in resource-limited settings (RLS)
requires prior understanding of HIV-1 integrase variants and conserved regions. Therefore …

T97A is an HIV-1 integrase polymorphism associated with integrase strand transfer inhibitor
(INSTI) resistance. Using pooled data from 16 clinical studies, we investigated the …

To the Editors: An estimated 36.9 million people are living with HIV-1 worldwide, 1 of which
there are approximately 75,500 infected people in Canada. 2 Although varied prevention …

Background HIV integrase inhibitor use is limited by low genetic barrier to resistance and
possible cross-resistance among representatives of this class of antiretrovirals. The aim of …

Objective The integrase strand-transfer inhibitors (INSTIs) are an important class in the
arsenal of antiretroviral drugs designed to block the integration of HIV-1 cDNA into the host …

As sub-Saharan Africa (SSA) countries are transitioning to dolutegravir (DTG)-based ART,
baseline data are required for optimal monitoring of therapeutic response. In this frame, we …

Raltegravir, an integrase inhibitor, is not a component of the current South African
antiretroviral treatment guidelines, but it could be introduced in the near future as cases of …

HIV‐1 genetic diversity and drug resistance mutations remain public health challenges
especially in regions where treatment is limited. The aim of this study was to characterize the …